Home      About this journal      Authors      Editors      Readers      Archive      Contact us
Clinical observation on therapeutic effect of nonalcoholic steatohepatitis through bianbing and bianzheng
Hits 1489  Download times 1378  Received:June 11, 2009  
View Full Text  View/Add Comment  Download reader
DOI   10.11656/j.issn.1672-1519.2009.04.11
Key Words   nonalcoholic steatohepatitis;bianbing;bianzheng;clinical observation on therapeutic effect
Author NameAffiliation
WANG Li-xin Tainjin Limited Company of Metallurgy Clique, Tianjin 300000, China 
Abstract
    [Objective] To observe the clinical effect in treating nonalcoholic steatohepatitis(NASH) through bianbing(disease differentiation) and bianzheng(syndrome differentiation). [Methods] One hundred and twenty subjects with NASH were randomly divided into two groups. The patients in bianbing group took Shugan Pills, and those in bianzheng group were treated with pills modified from Shugan Pills according to Traditional Chinese Medicine Syndrome type. All these patients were followed up 3 months to observe the changes in symptom, liver function, blood-lipid and USG. [Results] Thirty one cases were cured, 15 cases were excellent, 5 cases were efficacious, 9 cases were ineffective, and the cure rate was 85.0% in bianzheng group. Twenty eight cases were cured, 14 cases were excellent, 7 cases were efficacious, and 11 cases were ineffective, and the cured rate was 81.7% in the bianbing group. There were significant differences in the total effective rates between before and after therapy in both of the two groups (P<0.01). But there was no significant difference between the cure rates of two groups (P>0.05). [Conclusion] Both Shugan Pills and its modified pills has obvious clinical effect in treating NASH, and there was no significant difference between the two methods.

You are the 2300598 visitor.

Copyright @ 2007
Address: 10 Boyanghu Road, West District of Tuanbo New City, Jinghai District, Tianjin 301617, China  Postcode:
Tel:  Fax:  E-mail:
Beijing E-Tiller Co., Ltd.